Skip to main content
Top
Published in: Critical Care 5/2010

Open Access 01-10-2010 | Research

Interleukin-10 gene down-expression in circulating mononuclear cells during infusion of drotrecogin-α activated: a pilot study

Authors: Thomas Lavaux, Pascal Bilbault, Anne Launoy, Marie-Pierre Gaub, Pierre Oudet, Francis Schneider

Published in: Critical Care | Issue 5/2010

Login to get access

Abstract

Introduction

The purpose of this study was to investigate the gene expression of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α) and interleukin-10 (IL-10) in circulating mononuclear cells harvested from septic shock patients on drotrecogin-α activated (DAA) in order to determine whether this treatment has any effect on the inflammation phase.

Methods

We conducted a prospective cohort study in two intensive care departments. Blood samples were collected at inclusion (T1) and 36 hours later (T2) to measure plasma cytokines and the changes in intracellular TNF-α, IL-10 and IFN-γ mRNA expressions using the real-time quantitative polymerase chain reaction (RT-qPCR). Thirty-two septic shock patients were included: 16 with DAA at 24 μg/kg/h for 96 hours (DAA+) and 16 control (DAA-) eligible but contraindicated for DAA because of low platelet count.

Results

The basal characteristics were similar in both groups: mortality (50%), plasma cytokine concentrations, and baseline IFN-γ, TNF-α and IL-10 mRNA expressions (DAA+ vs. DAA-). At T2, there was a significant IFN-γ gene down-regulation in DAA+ but not in DAA- patients (-0.34 (-0.62; +1.54) vs. +1.41 (+0.35; +5.87), P = 0.008). In survivors, DAA administration was associated with a down-expression of both IFN-γ (-0.65 (-0.93; 0.48) vs. +0.7 (-0.04; +1.26), P = 0.01) and IL-10 (-0.78 (-0.92; -0.6) vs. -0.18 (-0.68; +0.46), P = 0.038). In the non-survivors, DAA infusion was associated with IL-10 over-expression when compared with survivors (+0.54 (-0.35; +11.52) vs. -0.78 (-0.92; -0.6), P < 0.001).

Conclusions

In this study, lack of IL-10 gene down-expression despite a 36-hour infusion of DAA is an ominous sign in septic shock patients suggesting that DAA is not able to reverse the outcome. Our results suggest that DAA can decrease the expression of anti-inflammatory cytokines in septic shock patients. IL-10 or IFN-γ gene down-expression could represent markers of DAA response.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRefPubMed Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRefPubMed
2.
go back to reference Macias WL, Yan SB, Williams MD, Um SL, Sandusky DE, Ballard DW, Planquois JM: New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care 2005, 9: S38-S45. 10.1186/cc3747PubMedCentralCrossRefPubMed Macias WL, Yan SB, Williams MD, Um SL, Sandusky DE, Ballard DW, Planquois JM: New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care 2005, 9: S38-S45. 10.1186/cc3747PubMedCentralCrossRefPubMed
3.
go back to reference Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 2005, 365: 63-78. 10.1016/S0140-6736(04)17667-8CrossRefPubMed Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 2005, 365: 63-78. 10.1016/S0140-6736(04)17667-8CrossRefPubMed
4.
go back to reference Salomao R, Martins PS, Brunialti MK, Fernandes Mda L, Martos LS, Mendes ME, Gomes NE, Rigato O: TLR signalling pathway in patients with sepsis. Shock 2008, Suppl 1: 73-77. 10.1097/SHK.0b013e318181af2aCrossRef Salomao R, Martins PS, Brunialti MK, Fernandes Mda L, Martos LS, Mendes ME, Gomes NE, Rigato O: TLR signalling pathway in patients with sepsis. Shock 2008, Suppl 1: 73-77. 10.1097/SHK.0b013e318181af2aCrossRef
5.
go back to reference Joyce DE, Grinnell BW: Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med 2002, 30: S288-S293. 10.1097/00003246-200205001-00019CrossRefPubMed Joyce DE, Grinnell BW: Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med 2002, 30: S288-S293. 10.1097/00003246-200205001-00019CrossRefPubMed
6.
go back to reference Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31: 1250-1256. SCCM/ESICM/ACCP/ATS/SIS 10.1097/01.CCM.0000050454.01978.3BCrossRefPubMed Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31: 1250-1256. SCCM/ESICM/ACCP/ATS/SIS 10.1097/01.CCM.0000050454.01978.3BCrossRefPubMed
7.
go back to reference Le Gall JR, Lemeshow S, Saunier F: A new simplified acute physiology score (SAPS II) based on European/North American multicenter study. JAMA 1993, 270: 2957-2963. 10.1001/jama.270.24.2957CrossRefPubMed Le Gall JR, Lemeshow S, Saunier F: A new simplified acute physiology score (SAPS II) based on European/North American multicenter study. JAMA 1993, 270: 2957-2963. 10.1001/jama.270.24.2957CrossRefPubMed
8.
go back to reference Le Gall JR, Klar J, Lemeshow S, Saulnier F, Alberti C, Artigas A, Teres D: The logistic organ dysfunction system. A new way to assess organ dysfunction in the intensive care unit. JAMA 1996, 276: 802-810. 10.1001/jama.276.10.802CrossRefPubMed Le Gall JR, Klar J, Lemeshow S, Saulnier F, Alberti C, Artigas A, Teres D: The logistic organ dysfunction system. A new way to assess organ dysfunction in the intensive care unit. JAMA 1996, 276: 802-810. 10.1001/jama.276.10.802CrossRefPubMed
9.
go back to reference Bilbault P, Lavaux T, Launoy A, Gaub MP, Meyer N, Oudet P, Pottecher T, Jaeger A, Schneider F: Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients. Crit Care Med 2007, 35: 69-75. 10.1097/01.CCM.0000251133.26979.F4CrossRefPubMed Bilbault P, Lavaux T, Launoy A, Gaub MP, Meyer N, Oudet P, Pottecher T, Jaeger A, Schneider F: Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients. Crit Care Med 2007, 35: 69-75. 10.1097/01.CCM.0000251133.26979.F4CrossRefPubMed
10.
go back to reference Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method. Methods 2001, 25: 402-408. 10.1006/meth.2001.1262CrossRefPubMed Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method. Methods 2001, 25: 402-408. 10.1006/meth.2001.1262CrossRefPubMed
11.
go back to reference Lorenz E, Mira JP, Frees KL, Schwartz DA: Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002, 162: 1028-1032. 10.1001/archinte.162.9.1028CrossRefPubMed Lorenz E, Mira JP, Frees KL, Schwartz DA: Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002, 162: 1028-1032. 10.1001/archinte.162.9.1028CrossRefPubMed
12.
go back to reference Scumpia PO, Moldawer LL: Biology of interleukin-10 and its regulatory roles in sepsis syndrome. Crit Care Med 2005, 33: S468-S471. 10.1097/01.CCM.0000186268.53799.67CrossRefPubMed Scumpia PO, Moldawer LL: Biology of interleukin-10 and its regulatory roles in sepsis syndrome. Crit Care Med 2005, 33: S468-S471. 10.1097/01.CCM.0000186268.53799.67CrossRefPubMed
14.
go back to reference Kox WJ, Volk T, Kox SN, Volk HD: Immunomodulatory therapies in sepsis. Intensive Care Med 2000, 26: S124-S128. 10.1007/s001340051129CrossRefPubMed Kox WJ, Volk T, Kox SN, Volk HD: Immunomodulatory therapies in sepsis. Intensive Care Med 2000, 26: S124-S128. 10.1007/s001340051129CrossRefPubMed
15.
go back to reference Toltl LJ, Beaudin S, Liaw PC, Canadian Critical Care Translational Biology Group: Activated protein C up-regulates IL-10 and inhibits tissue factor in blood monocytes. J Immunol 2008, 181: 2165-2173.CrossRefPubMed Toltl LJ, Beaudin S, Liaw PC, Canadian Critical Care Translational Biology Group: Activated protein C up-regulates IL-10 and inhibits tissue factor in blood monocytes. J Immunol 2008, 181: 2165-2173.CrossRefPubMed
16.
go back to reference Levy H, Small D, Heiselman DE, Riker R, Steingrub J, Chen R, Qualy RL, Darstein C, Mongan E: Obesity does not alter the pharmacokinetics of drotrecogin alpha (activated) in severe sepsis. Ann Pharmacother 2005, 39: 262-267. 10.1345/aph.1E386CrossRefPubMed Levy H, Small D, Heiselman DE, Riker R, Steingrub J, Chen R, Qualy RL, Darstein C, Mongan E: Obesity does not alter the pharmacokinetics of drotrecogin alpha (activated) in severe sepsis. Ann Pharmacother 2005, 39: 262-267. 10.1345/aph.1E386CrossRefPubMed
Metadata
Title
Interleukin-10 gene down-expression in circulating mononuclear cells during infusion of drotrecogin-α activated: a pilot study
Authors
Thomas Lavaux
Pascal Bilbault
Anne Launoy
Marie-Pierre Gaub
Pierre Oudet
Francis Schneider
Publication date
01-10-2010
Publisher
BioMed Central
Published in
Critical Care / Issue 5/2010
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc9252

Other articles of this Issue 5/2010

Critical Care 5/2010 Go to the issue